Manuscripts
Showing 1572 manuscripts.
Efficacy, safety, and tolerability of dispersible and immediate release abacavir/dolutegravir/lamivudine tablets in children with HIV: IMPAACT 2019 week 48 results
Citation
Helena Rabie, Dwight E. Yin, Shawn Ward, Yasha Rani, Lauren Ziemba, Kristina M. Brooks, Tim R. Cressey, Gaerolwe R. Masheto, Haseena Cassim, Jaime G. Deville, Ponego L. Ponatshego, Faeezah Patel, Linda Aurpibul, Shaun L. Barnabas, Iris Mustich, Anne Coletti, Barbara Heckman, Chelsea Krotje, Ellen Townley, Jack Moye, Sai Majji, Edward P. Acosta, Kevin Ryan, Hardik Chandasana, Cynthia H. Brothers, Ann M. Buchanan, Patricia M. Flynn, IMPAACT 2019 Study Team. Efficacy, safety, and tolerability of dispersible and immediate release abacavir/dolutegravir/lamivudine tablets in children with HIV: IMPAACT 2019 week 48 results. 2025. PMID: 40440679Year
          2025      
Study
          IMPAACT 2019      
Inflammation, antiretroviral therapy continuation, and HIV disease progression in postpartum women with HIV
Citation
Rupak SHIVAKOTI, Mark J. Giganti, Michael M Lederman, Rachel Ketchum, Sean S. Brummel, Daniela Moisi, Allen T Matubu, Sufia Dadabhai, Dhayendre Moodley, Avy Violari, Lameck Chinula, Maxensia Owor, Amita Gupta, Taha E. Taha, Patricia M. Flynn, Judith S. Currier, Mary Glenn Fowler, PROMISE Study Team. Inflammation, antiretroviral therapy continuation, and HIV disease progression in postpartum women with HIV. AIDS. 2025. PMID: 40476693Year
          2025      
Journal
          AIDS      
Study
          1077BF,          1077FF      
Pharmacokinetics of first-line tuberculosis drugs rifampin,
isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study
  
  
    Citation
Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B. Theron, Mark F. Cotton, Ahizechukwu C. Eke, Tim R. Cressey, Deo Wabwire, David E. Shapiro, Kira Bacon, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Kittipong Rungruengthanakit, Lubbe Wiesner, Edmund V. Capparelli, Alice M. Stek, Mark Mirochnick, Brookie M. Best, IMPAACT P1026s Protocol Team. Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study. Journal Antimicrobial Agents and Chemotherapy. 2025. PMID: 40741959Year
          2025      
Journal
          Journal Antimicrobial Agents and Chemotherapy      
Study
          P1026S      
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV
Citation
Nicole H. Tobin, Sarah Brooker, Fan Li, Yoninah S. Cramer, Susan Rosenkranz, Robert W. Coombs, Susan E. Cohn, Carmen Zorrilla, Laura Moran, Baiba Berzins, Kimberly K. Scarsi, Catherine Godfrey, Grace M. Aldrovandi, ACTG 5316 Team. Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV. Journal of Infectious Diseases. 2025. 231: 583-594. PMID: 39479902Year
          2025      
Journal
          Journal of Infectious Diseases      
Altered milk tryptophan and tryptophan metabolites and health of children born to women with HIV
Citation
Nicole H. Tobin, Fan Li, Wentao Zhu, Kathie G. Ferbas, John W. Sleasman, Daniel Raftery, Louise Kuhn, Grace M. Aldrovandi. Altered milk tryptophan and tryptophan metabolites and health of children born to women with HIV. Research Square. 2025. 3PMID: 40166030Year
          2025      
Journal
          Research Square      
Mixing of Tecovirimat in Water to Support Oral Dosing of Infants and Children With Mpox
Citation
Z. Wei, Kristina Brooks, Sharon Nachman, Grace Aldrovandi, Timothy Wilkin, William Fischer, Jennifer Kiser, Jason Zucker. Mixing of Tecovirimat in Water to Support Oral Dosing of Infants and Children With Mpox. 2025. PMID: 39953939Year
          2025      
Study
          A5418      
Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens
Citation
Christopher Alba, Shelly Malhotra, Stephanie Horsfall, Matthew E. Barnhart, Adrie Bekker, Katerina Chapman, Coleen K. Cunningham, Patricia E. Fast, Genevieve G. Fouda, Kenneth A. Freedberg, Ameena Goga, Lusine R. Ghazaryan, Valériane Leroy, Carlyn Mann, Margaret M. McCluskey, Elizabeth J. McFarland, Vincent Muturi-Kioi, Sallie R. Permar, Roger Shapiro, Devin Sok, Lynda Stranix-Chibanda, Milton C. Weinstein, Andrea L. Ciaranello, Caitlin M. Dugdale. Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLoS One. 2025. 20: e0318940. PMID: 40106399Year
          2025      
Journal
          PLoS One      
Study
          P1112      
Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates
Citation
Itzayana G Miller, Aakash Mahant Mahant, Jennifer A Jenks, Eleanor C Semmes, Eric Rochat, Savannah L Herbek, Caroline Andy , Nicole S Rodgers, Justin Pollara, Linda M Gerber, Betsy C Herold, Sallie R Permar. Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates. Viruses. 2025. 17: 325. PMID: 40143253Year
          2025      
Journal
          Viruses      
ART-free HIV-1 remission in children with in-utero HIV-1
after very early ART (IMPAACT P1115): a multicentre,
open-label, phase 1/2 proof-of-concept study
  
  Citation
Deborah Persaud, Anne Coletti, Bryan S. Nelson, Jennifer Jao, Edmund V. Capparelli, Diane Costello, Camlin Tierney, Adeodata R. Kekitiinwa, Teacler Nematadzira, Boniface N. Njau, John Moye, Patrick Jean-Philippe, Violet Korutaro, Annet Nalugo, Tapiwa Mbengeranwa, Tinashe Chidemo, Blandina T. Mmbaga, Philoteus A. Sakasaka, Mark Cotton, Cheryl Jennings, Carly Hoffmann, Laura Hovind, Yvonne Bryson, Ellen G Chadwick, IMPAACT P1115 Study Team. ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study. Lancet HIV. 2025.Year
          2025      
Journal
          Lancet HIV      
Study
          P1115      
ART-free HIV-1 remission in children with in-utero HIV-1
after very early ART (IMPAACT P1115): a multicentre,
open-label, phase 1/2 proof-of-concept study
  
  Citation
Deborah Persaud, Anne Coletti, Bryan S. Nelson, Jennifer Jao, Edmund Capparelli, Diane Costello, Camlin Tierney, Adeodata R. Kekitiinwa, Teacler Nematadzira, Boniface N. Njau, John Moye, Patrick Jean-Philippe, Violet Korutaro, Annet Nalugo, Tapiwa Mbengeranwa, Tinashe Chidemo, Blandina T. Mmbaga, Philoteus A. Sakasaka, Mark Cotton, Cheryl Jennings, Carly Hoffmann, Laura Hovind, Scott Watson, Yvonne Bryson, Ellen G. Chadwick, IMPAACT P1115 Study Team. ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study. New England Journal of Medicine. 2025.Year
          2025      
Journal
          New England Journal of Medicine      
Study
          P1115